Bayer Aktiengesellschaft - BAYRY Stock Price Target and Predictions

  • Consensus Rating: Reduce
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 10
  • Breakdown:
  • 1 Sell Ratings
  • 9 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$6.98
▼ -0.02 (-0.29%)

This chart shows the closing price for BAYRY by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Bayer Aktiengesellschaft Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for BAYRY and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for BAYRY

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 10 analysts offering 12 month price targets for Bayer Aktiengesellschaft in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $6.98.

This chart shows the closing price for BAYRY for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Reduce

The current consensus among 10 investment analysts is to reduce stock in Bayer Aktiengesellschaft. This Reduce consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 9 hold ratings
  • 1 sell ratings
1/1/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 9 hold ratings
  • 1 sell ratings
4/1/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 9 hold ratings
  • 1 sell ratings
6/30/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 9 hold ratings
  • 1 sell ratings
9/28/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 9 hold ratings
  • 1 sell ratings
12/27/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 9 hold ratings
  • 1 sell ratings
3/26/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 9 hold ratings
  • 1 sell ratings
5/25/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 9 hold ratings
  • 1 sell ratings
6/24/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 9 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
5/30/2024The Goldman Sachs GroupInitiated CoverageNeutral
3/7/2024Sanford C. BernsteinReiterated RatingOutperform ➝ Market Perform
2/29/2024CitigroupReiterated RatingBuy ➝ Neutral
1/30/2024Wolfe ResearchDowngradeOutperform ➝ Peer Perform
12/18/2023HSBCDowngradeHold ➝ Reduce
12/4/2023UBS GroupDowngradeBuy ➝ Neutral
11/21/2023Jefferies Financial GroupDowngradeBuy ➝ Hold
11/14/2023Deutsche Bank AktiengesellschaftDowngradeBuy ➝ Hold
10/10/2023HSBCUpgradeReduce ➝ Hold
9/25/2023Redburn AtlanticDowngradeOverweight ➝ Neutral
8/16/2023Berenberg BankDowngradeBuy ➝ Hold
7/19/2023Wolfe ResearchInitiated CoverageOutperform
7/14/2023HSBCInitiated CoverageReduce
1/6/2023Morgan StanleyDowngradeOverweight ➝ Equal Weight
1/3/2023JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral
12/5/2022Bank of AmericaDowngradeBuy ➝ Neutral
11/14/2022Berenberg BankLower TargetBuy ➝ Buy€76.00 ➝ €70.00
11/9/2022Morgan StanleyLower Target€81.00 ➝ €80.00
11/9/2022JPMorgan Chase & Co.Lower TargetOverweight ➝ Overweight€80.00 ➝ €77.00
11/9/2022Societe GeneraleLower TargetHold ➝ Hold€69.00 ➝ €54.00
10/26/2022Morgan StanleyBoost Target€80.00 ➝ €81.00
9/7/2022Morgan StanleyLower TargetOverweight ➝ Overweight€87.00 ➝ €80.00
8/31/2022JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight€75.00 ➝ €80.00
8/30/2022Exane BNP ParibasUpgradeNeutral ➝ Outperform
8/16/2022Deutsche Bank AktiengesellschaftBoost TargetBuy ➝ Buy€75.00 ➝ €79.00
7/20/2022Morgan StanleyBoost TargetOverweight ➝ Overweight€83.00 ➝ €85.00
5/19/2022UBS GroupBoost TargetBuy ➝ Buy€90.00 ➝ €96.00
5/11/2022BarclaysBoost TargetOverweight ➝ Overweight€85.00 ➝ €90.00
4/25/2022Morgan StanleyBoost TargetOverweight ➝ Overweight€77.00 ➝ €83.00
4/5/2022BarclaysUpgradeEqual Weight ➝ Overweight
3/14/2022Jefferies Financial GroupInitiated CoverageBuy
3/11/2022UBS GroupBoost Target€85.00 ➝ €90.00
2/24/2022BarclaysBoost TargetEqual Weight ➝ Equal Weight€50.00 ➝ €55.00
1/31/2022CitigroupUpgradeNeutral ➝ Buy
11/15/2021AlphaValueUpgradeBuy
11/10/2021JPMorgan Chase & Co.Reiterated RatingOverweight
11/10/2021Morgan StanleyReiterated RatingOverweight
11/10/2021Credit Suisse GroupReiterated RatingNeutral
10/29/2021Kepler Capital MarketsReiterated RatingBuy
10/21/2021Morgan StanleyReiterated RatingOverweight
8/9/2021Berenberg BankLower TargetBuy€74.00 ➝ €60.00
8/6/2021Credit Suisse GroupReiterated RatingNeutral
8/4/2021AlphaValueDowngradeBuy
6/25/2021Kepler Capital MarketsReiterated RatingBuy
5/26/2021DZ BankReiterated RatingBuy
5/19/2021Morgan StanleyReiterated RatingOverweight
5/18/2021JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight
5/14/2021DZ BankReiterated RatingBuy
5/13/2021Credit Suisse GroupReiterated RatingNeutral
5/13/2021Bryan, Garnier & CoUpgradeSell ➝ Neutral
3/30/2021DZ BankReiterated RatingBuy
3/19/2021Deutsche Bank AktiengesellschaftReiterated RatingBuy
3/11/2021Societe GeneraleReiterated RatingHold
3/4/2021Berenberg BankReiterated RatingBuy
3/1/2021Morgan StanleyReiterated RatingOverweight
3/1/2021DZ BankReiterated RatingBuy
2/26/2021Credit Suisse GroupReiterated RatingNeutral
2/10/2021BarclaysReiterated RatingEqual Weight
2/4/2021DZ BankReiterated RatingBuy
1/27/2021Deutsche Bank AktiengesellschaftReiterated RatingBuy
1/20/2021Credit Suisse GroupReiterated RatingNeutral
1/8/2021Morgan StanleyReiterated RatingOverweight
1/6/2021Nord/LBReiterated RatingBuy
11/6/2020Morgan StanleyReiterated RatingOverweight
11/5/2020Deutsche Bank AktiengesellschaftReiterated RatingBuy
11/5/2020JPMorgan Chase & Co.Reiterated RatingNeutral
11/4/2020Credit Suisse GroupReiterated RatingNeutral
10/21/2020Morgan StanleyReiterated RatingOverweight
10/13/2020BarclaysDowngradeOverweight ➝ Equal Weight
10/5/2020UBS GroupReiterated RatingBuy
10/2/2020Deutsche Bank AktiengesellschaftReiterated RatingBuy
10/2/2020AlphaValueDowngradeBuy
10/1/2020Bryan, Garnier & CoDowngradeNeutral ➝ Sell
10/1/2020CitigroupDowngradeBuy ➝ Neutral
10/1/2020HSBCDowngradeBuy ➝ Hold
10/1/2020CommerzbankDowngradeBuy ➝ Hold
9/14/2020Morgan StanleyReiterated RatingOverweight
9/9/2020BMO Capital MarketsInitiated CoverageMarket Perform
9/3/2020Credit Suisse GroupInitiated CoverageNeutral
8/11/2020Deutsche Bank AktiengesellschaftReiterated RatingBuy
8/10/2020Morgan StanleyReiterated RatingOverweight
6/26/2020JPMorgan Chase & Co.Reiterated RatingNeutral
6/26/2020Deutsche Bank AktiengesellschaftReiterated RatingBuy
6/25/2020Morgan StanleyReiterated RatingOverweight
6/25/2020HSBCUpgradeHold ➝ Buy
6/16/2020CommerzbankUpgradeHold ➝ Buy
4/22/2020Morgan StanleyReiterated RatingOverweight
3/4/2020Deutsche Bank AktiengesellschaftUpgradeHold ➝ Buy
12/17/2019Berenberg BankUpgradeHold ➝ Buy
8/16/2019Bank of AmericaUpgradeNeutral ➝ Buy
(Data available from 6/24/2019 forward)

News Sentiment Rating

0.51 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 33 positive mentions
  • 18 negative mentions
  • 11 very negative mentions
11/27/2023
  • 3 very positive mentions
  • 16 positive mentions
  • 4 negative mentions
  • 2 very negative mentions
12/27/2023
  • 4 very positive mentions
  • 19 positive mentions
  • 3 negative mentions
  • 1 very negative mentions
1/26/2024
  • 6 very positive mentions
  • 48 positive mentions
  • 13 negative mentions
  • 14 very negative mentions
2/25/2024
  • 13 very positive mentions
  • 39 positive mentions
  • 10 negative mentions
  • 6 very negative mentions
3/26/2024
  • 13 very positive mentions
  • 54 positive mentions
  • 12 negative mentions
  • 4 very negative mentions
4/25/2024
  • 16 very positive mentions
  • 55 positive mentions
  • 7 negative mentions
  • 1 very negative mentions
5/25/2024
  • 5 very positive mentions
  • 4 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
6/24/2024

Current Sentiment

  • 5 very positive mentions
  • 4 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Bayer Aktiengesellschaft logo
Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and digital solutions, and contrast agents, as well as cell and gene therapy. The Consumer Health segment markets nonprescription over-the-counter medicines for self-medication and self-care; and solutions for nutritional supplements, allergy, cough and cold, dermatology, pain and cardiovascular risk prevention, and digestive health. The Crop Science segment offers seeds, improved plant traits, innovative chemical and biological crop protection products, digital solutions, as well as customer service for agriculture. This segment also provides breeding, propagation, and production/processing of seeds, including seed dressing. The company has a collaboration with Acuitas Therapeutics, Inc. to strengthen gene editing programs; Peking University in the area of basic pharmaceutical research; the Swiss Tropical and Public Health Institute in the development of the compound emodepside for the treatment of infection with soil-transmitted helminths; bit.bio Ltd. for the discovery and manufacture of regulatory T cells for use in creating therapeutics; Hologic, Inc. in the field of contrastenhanced-mammography solutions to improve diagnostic imaging for the detection of breast cancer; and Twist Bioscience Corporation centering around the research and development of antibody-based pharmaceuticals, as well as with CrossBay Medical Inc. It distributes its products through wholesalers, pharmacies and pharmacy chains, supermarkets, online and other retailers, and hospitals, as well as directly to farmers. The company has collaboration with Thermo Fisher Scientific. Bayer Aktiengesellschaft was founded in 1863 and is based in Leverkusen, Germany.
Read More

Today's Range

Now: $6.98
Low: $6.95
High: $7.01

50 Day Range

MA: $7.48
Low: $6.98
High: $8.02

52 Week Range

Now: $6.98
Low: $6.92
High: $14.70

Volume

501,900 shs

Average Volume

1,745,329 shs

Market Capitalization

N/A

P/E Ratio

N/A

Dividend Yield

0.31%

Beta

1.1

Frequently Asked Questions

What sell-side analysts currently cover shares of Bayer Aktiengesellschaft?

The following Wall Street analysts have issued reports on Bayer Aktiengesellschaft in the last twelve months: Berenberg Bank, Citigroup Inc., Deutsche Bank Aktiengesellschaft, HSBC Holdings plc, Jefferies Financial Group Inc., Redburn Atlantic, Sanford C. Bernstein, The Goldman Sachs Group, Inc., UBS Group AG, and Wolfe Research.
View the latest analyst ratings for BAYRY.

What is the current price target for Bayer Aktiengesellschaft?

0 Wall Street analysts have set twelve-month price targets for Bayer Aktiengesellschaft in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Bayer Aktiengesellschaft in the next year.
View the latest price targets for BAYRY.

What is the current consensus analyst rating for Bayer Aktiengesellschaft?

Bayer Aktiengesellschaft currently has 1 sell rating and 9 hold ratings from Wall Street analysts. The stock has a consensus analyst rating of "Reduce."
View the latest ratings for BAYRY.

What other companies compete with Bayer Aktiengesellschaft?

Other companies that are similar to Bayer Aktiengesellschaft include CSL, Bristol-Myers Squibb, GSK, Zoetis and Takeda Pharmaceutical. Learn More about companies similar to Bayer Aktiengesellschaft.

How do I contact Bayer Aktiengesellschaft's investor relations team?

Bayer Aktiengesellschaft's physical mailing address is Kaiser-Wilhelm-Allee 1, Leverkusen 2M, 51368. The company's listed phone number is 49214301 and its investor relations email address is [email protected]. The official website for Bayer Aktiengesellschaft is www.bayer.com. Learn More about contacing Bayer Aktiengesellschaft investor relations.